Dossier
pubmed
news report
Semaglutide Demonstrates Benefits Across Frailty Levels.
Key claim: Semaglutide is reported to show clinical benefits across the spectrum of frailty levels.
Abstract
No abstract available.
Why this matters
Framing semaglutide benefits as holding across the frailty spectrum extends the AOM-as-longevity-therapy narrative into older and frailer adults, the group where benefit-risk calculus is most contested. The underlying signal traces to a post-hoc SELECT analysis already logged on this page; the news coverage itself is a trend indicator, not fresh evidence.